Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN).

Authors
Publication date
1 January 2016
Publisher
'American Society of Clinical Oncology (ASCO)'

Abstract

International audienceno abstrac

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Hal-Diderot

    redirect
    oaioai:HAL:hal-01361499v1
    Last time updated on 14/04/2021